ARTICLE | Company News
Biovitrum, Resistentia deal
November 13, 2006 8:00 AM UTC
BVT will manufacture RES 08, the biopharmaceutical substance in Resistentia's RP01, for Phase III trials to treat allergy. Resistentia expects the protein immunotherapeutic that induces the production...